Summit Therapeutics, A Top 1% Biotech, Plummets On A High-Profile Failure
In This Article:
Summit Therapeutics stock plunged Friday after its highly watched cancer drug failed to significantly improve overall survival.
Oops, something went wrong
Summit Therapeutics stock plunged Friday after its highly watched cancer drug failed to significantly improve overall survival.